Long‑term complete response in a patient with postoperative recurrent ALK‑rearranged lung adenocarcinoma treated with crizotinib: A case report

  • Authors:
    • Takayuki Kosaka
    • Toshiki Yajima
    • Ei Yamaki
    • Seshiru Nakazawa
    • Kenji Tomizawa
    • Ryoichi Onozato
    • Ayako Yamazaki
    • Junko Hirato
    • Yasushi Yatabe
    • Kimihiro Shimizu
    • Akira Mogi
    • Ken Shirabe
  • View Affiliations

  • Published online on: July 3, 2019     https://doi.org/10.3892/mco.2019.1892
  • Pages: 309-312
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Anaplastic lymphoma kinase (ALK) gene rearrangements are identified in approximately 5% of patients with non‑small cell lung cancer (NSCLC). Despite initial dramatic responses to ALK inhibitors, the majority of patients relapse within 1 year, owing to the development of resistance. Herein we present a case of variant type 2 ALK‑rearranged lung adenocarcinoma recurrence with multiple lung metastasis that maintained complete response over 5 years with crizotinib, which is the first approved ALK inhibitor. The efficacy of crizotinib may vary among ALK fusion variants and thus, variant type may represent an important factor in guiding the treatment strategy for ALK‑rearranged lung adenocarcinoma.
View Figures
View References

Related Articles

Journal Cover

September 2019
Volume 11 Issue 3

Print ISSN: 2049-9450
Online ISSN:2049-9469

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Kosaka, T., Yajima, T., Yamaki, E., Nakazawa, S., Tomizawa, K., Onozato, R. ... Shirabe, K. (2019). Long‑term complete response in a patient with postoperative recurrent ALK‑rearranged lung adenocarcinoma treated with crizotinib: A case report. Molecular and Clinical Oncology, 11, 309-312. https://doi.org/10.3892/mco.2019.1892
MLA
Kosaka, T., Yajima, T., Yamaki, E., Nakazawa, S., Tomizawa, K., Onozato, R., Yamazaki, A., Hirato, J., Yatabe, Y., Shimizu, K., Mogi, A., Shirabe, K."Long‑term complete response in a patient with postoperative recurrent ALK‑rearranged lung adenocarcinoma treated with crizotinib: A case report". Molecular and Clinical Oncology 11.3 (2019): 309-312.
Chicago
Kosaka, T., Yajima, T., Yamaki, E., Nakazawa, S., Tomizawa, K., Onozato, R., Yamazaki, A., Hirato, J., Yatabe, Y., Shimizu, K., Mogi, A., Shirabe, K."Long‑term complete response in a patient with postoperative recurrent ALK‑rearranged lung adenocarcinoma treated with crizotinib: A case report". Molecular and Clinical Oncology 11, no. 3 (2019): 309-312. https://doi.org/10.3892/mco.2019.1892